Peptide Dosing Charts
The approved titration schedules, reproduced from the FDA prescribing information and cited to it. Print or save as PDF directly — nothing here is behind an email form.
How to use a printed chart without getting hurt by it
Every chart below is in milligrams, because that is the unit the labels use. Your syringe is not. A U-100 barrel is graduated in hundredths of a millilitre, so no chart of doses can tell you where to stop the plunger — that depends on the concentration of your own vial, which is a number only you know. A chart taped to a fridge and a syringe in your hand are measuring two different quantities, and the step between them is a division you have to do.
Two habits close that gap. Write the concentration on the vial in permanent marker the moment you reconstitute it, because it cannot be recovered from looking at the solution afterwards. And convert once, at the start of a titration step, rather than each time you inject — a dose that lands between the printed marks is worth catching when you have time to fix it with a different water volume, not at the moment of injection.
What these charts deliberately leave out
- Weight-based scaling. None of these labels scales the adult dose to body weight. Charts elsewhere that offer a mg/kg figure for a GLP-1 are adding something the label does not contain.
- Cross-drug conversion. There is no approved mapping between these schedules. Each starts at its own starting dose, whatever you were taking before.
- Doubling up after a missed dose. The labels give windows for taking a late dose and instructions for skipping it; none of them describes making up a missed dose by taking more.
- Doses above the approved maximum. Each ladder below ends where its label ends. Where a compounded vial is sold at a strength beyond that, no schedule exists for it and none is invented here.
Tirzepatide — Zepbound (weight management)
The dosage may be increased in 2.5 mg increments after at least 4 weeks on the current dose. The label is explicit that the 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage. The maximum is 15 mg once weekly.
Source: ZEPBOUND (tirzepatide) injection — FDA prescribing information
Tirzepatide calculator →Semaglutide — Wegovy (weight management)
One escalation every 4 weeks. If a dose is not tolerated, the label says to consider delaying escalation by 4 weeks rather than pushing on.
Source: WEGOVY (semaglutide) injection and tablets — FDA prescribing information
Semaglutide calculator →Liraglutide — Saxenda (weight management)
Escalates weekly, not every 4 weeks. The label sets a stopping rule: review at 16 weeks and discontinue if the patient has not lost at least 4% of baseline body weight.
Source: SAXENDA (liraglutide) injection — FDA prescribing information
Liraglutide calculator →Why there is no chart for the other 25
Because no approved dosing schedule exists for them, anywhere. Publishing a tidy “BPC-157 dosing chart” would mean inventing one, and the cheat sheets circulating online do exactly that. What we publish instead, on each compound’s own page, is the doses that appeared in named studies — labelled with the species they were given to and the route they were given by.
Browse all peptides →Why none of this is gated
The standard pattern in this niche is a free calculator with a “dosing chart” or “protocol PDF” behind an email form. It is worth noticing which half gets gated. The arithmetic is free everywhere, because it is the same three lines of division wherever you find it. The chart is the part that tends to contain numbers nobody can source — which is precisely why it sits behind the form rather than on the page, where it could be checked.
Everything here comes from a document you can open, which is also why it can be printed without asking you for anything.
Sources
Every schedule above is reproduced from the prescribing information named here. Open the label and check the table against it — that is the point of printing the source next to the chart.
- FDA labelFDA / DailyMed· 2026-08ZEPBOUND (tirzepatide) injection — FDA prescribing information
- FDA labelFDA· 2026-03WEGOVY (semaglutide) injection and tablets — FDA prescribing information
- FDA labelFDA / DailyMedSAXENDA (liraglutide) injection — FDA prescribing information
- GuidelineInternational Organization for Standardization· 2016-03ISO 8537:2016 — Sterile single-use syringes, with or without needle, for insulin (scope and requirements; full text not public)
- Published studyDiabetology International 2024;15(3):544–549· 2024-05Kondo M, Saji R, Yamada Y, et al. Analysis of factors affecting the accuracy of low-dose insulin dosage using syringes and vials
- RegulatorFDA· 2026-09-01FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss